Notably, there was an increase in the frequencies of NKG2D+TIGIT− Vδ1 cells and NKG2D−TIGIT+ Vδ2 cells in AML patients who achieved CR after chemotherapy, indicating the relevance of γδ T-cell subsets and clinical outcomes of AML patients. This evidence concerns the gene KLRK1 and acute myeloid leukemia.